Health Canada has approved Trikafta as a triple-combination therapy for people with cystic fibrosis (CF), ages 12 and up, who have at least one F508del mutation, the most common CF-causing mutation. This decision is expected to give about 1,100 people access for a first time to a therapy that directly…
To help patient advocacy leaders and their partners better understand how global health statistics codes — known as ICD codes — are assigned, updated, and revised in the U.S. health information system, the EveryLife Foundation for Rare Diseases is presenting a first-of-its-kind resource guide. The foundation created the…
A new strategy to correct so-called splicing mutations could help deliver nucleic acid therapies called oligonucleotides to cells in the lung, a new study suggests. This approach may aid in the development of new treatments for people with cystic fibrosis (CF), according to researchers. “With our oligonucleotide delivery platform,…
A mobile, dietary self-monitoring app used for six months to track food choices and manage pancreatic enzyme replacement therapy (PERT) helped children with cystic fibrosis (CF) to better meet disease-specific nutritional guidelines, a study shows. Still, the nutritional changes made were not sufficient to reach the standards of…
Those who wish to gain practical tools for living optimally with rare diseases are encouraged to attend the annual Living Rare Living Stronger Patient and Family Forum, hosted by the National Organization for Rare Disorders (NORD) and set this year for June 26-27. The conference brings together patients,…
A collaboration between the Cystic Fibrosis Foundation and Deep Science Ventures aims to identify technologies that might overcome the challenges inherent in developing gene therapies for cystic fibrosis (CF). The effort is part of the foundation’s Path to a Cure initiative, a $500 million research program whose focus…
BX004, a phage therapy candidate for Pseudomonas aeruginosa infections in people with cystic fibrosis (CF), was able to effectively kill a range of antibiotic-resistant bacterial strains under laboratory conditions, new data show. These findings were shared in the poster “Phage therapy for chronic Pseudomonas aeruginosa infections in Cystic Fibrosis…
The first participants have been dosed in the first clinical trial testing EDT001, an investigational therapy for cystic fibrosis (CF) being developed by Enterprise Therapeutics. The trial is being conducted in healthy participants (without CF) to assess the investigational medicine’s safety profile. “We are excited to be entering…
RCT223 and RTX0001, ReCode Therapeutics’ experimental RNA-based therapies for cystic fibrosis (CF), safely restored function to CFTR, the faulty protein in CF, in patient-derived lung cells. Delivered through the company’s non-viral platform — called the selective organ targeting (SORT) lipid nanoparticle (LNP) platform — the therapies were also…
Children and adolescents on Symdeko (tezacaftor/ivacaftor) and Orkambi (ivacaftor/lumacaftor) for cystic fibrosis (CF) had higher treatment adherence rates compared with adults given the same CFTR modulators, a nationwide study in the U.S. found. The study also showed that adherence — patients choosing to follow through with a prescribed treatment —…
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Get regular updates to your inbox.